Lululemon Cuts 2026 Outlook as Weak North America Sales Pressure Growth 
Apollo and Blackstone Complete $35 Billion Anthropic AI Infrastructure Financing Deal 
SpaceX Sets IPO Price at $135 Per Share Ahead of Historic Nasdaq Debut 
Netflix Names Jay Hoag as Board Chairman Following Reed Hastings’ Departure 
Hyundai, Nvidia, and South Korea Near Deal for Major AI Technology Center 
DeepSeek Targets $7.4 Billion Funding Round, Valuation Could Reach $59 Billion in 2026 
Jensen Huang Strengthens Nvidia’s South Korea Ties Amid AI Expansion 
Foreign Firms Cash In on India's IPO Boom 
Quantinuum Raises $1.68 Billion in Upsized Nasdaq IPO Amid Growing Quantum Computing Demand 
Airbus Aircraft Deliveries Surge in May 2026 
Switch Eyes Multi-Billion-Dollar Funding Round at $50 Billion Valuation Ahead of Potential IPO 
Meta Challenges Australia’s Proposed Tech Tax, Citing U.S. Trade Agreement Concerns 
CrowdStrike Beats Q1 FY2027 Expectations, Raises Outlook Despite After-Hours Stock Decline 
Atlas Renewable Energy Freezes $1 Billion Brazil Investment Amid Renewable Energy Curtailment 
MOL Gets More Time to Negotiate Acquisition of Russian-Owned Stake in Serbia’s NIS 
Honeywell Aerospace Targets $6.5 Billion Earnings by 2030 After Spin-Off 
Bouygues, Orange and Iliad Strike €20.35 Billion Deal to Acquire SFR 
SAN DIEGO, Nov. 08, 2017 -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver failure, today announced that the company will participate in the Stifel 2017 Healthcare Conference in New York, NY.
The Company will be presenting at 9:30 AM Eastern on Wednesday, November 15, 2017. A live webcast of the presentation will be available on the Investor Relations page of the Company's website at: http://ir.vitaltherapies.com/. An archive of the presentation will be available for replay following the conference.
About Vital Therapies, Inc.
Vital Therapies, Inc. is a biotherapeutic company developing a cell-based therapy targeting the treatment of acute forms of liver failure. The Company’s ELAD System is an extracorporeal human allogeneic cellular liver therapy currently in phase 3 clinical trials. Vital Therapies, Inc. is based in San Diego, California. Vital Therapies® and ELAD® are trademarks of Vital Therapies, Inc.
Contact:
Vital Therapies, Inc.
Al Kildani
Vice President, Investor Relations and Business Development
858-673-6840
[email protected]
